Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C G Ericsson

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
European Heart Journal|August 26, 1998
Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progressC G Ericsson
Journal of Internal Medicine|March 1, 1990
Two-year survival after myocardial infarctionC G Ericsson, L Erhardt, N Rehnqvist
Drugs Under Experimental and Clinical Research|January 1, 1995
Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)U de Faire, C G Ericsson, A Hamsten, et al.
Acta Medica Scandinavica|January 1, 1984
Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarctionN Rehnqvist, C G Ericsson, S Eriksson, et al.
The American Journal of Cardiology|November 14, 1997
Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT])C G Ericsson, J Nilsson, L Grip, et al.
Acta Medica Scandinavica|January 1, 1983
Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarctionN Rehnqvist, L Erhardt, C G Ericsson, et al.
American Heart Journal|May 1, 1986
Repeated exercise and redistribution thallium-201 scintigrams in patients with myocardial infarction treated with timolol or placeboC G Ericsson, A Hamsten, A Granath, et al.
Journal of Internal Medicine|April 25, 2006
Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarctionA Samnegård, A Silveira, P Tornvall, et al.
European Heart Journal|December 1, 1996
Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)U de Faire, C G Ericsson, L Grip, et al.
Lancet (London, England)|March 30, 1996
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patientsC G Ericsson, A Hamsten, J Nilsson, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
European Heart Journal|August 26, 1998
Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progressC G Ericsson
Journal of Internal Medicine|March 1, 1990
Two-year survival after myocardial infarctionC G Ericsson, L Erhardt, N Rehnqvist
Drugs Under Experimental and Clinical Research|January 1, 1995
Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)U de Faire, C G Ericsson, A Hamsten, et al.
Acta Medica Scandinavica|January 1, 1984
Comparative investigation of the antiarrhythmic effect of propafenone (Rytmonorm) and lidocaine in patients with ventricular arrhythmias during acute myocardial infarctionN Rehnqvist, C G Ericsson, S Eriksson, et al.
The American Journal of Cardiology|November 14, 1997
Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT])C G Ericsson, J Nilsson, L Grip, et al.
Acta Medica Scandinavica|January 1, 1983
Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarctionN Rehnqvist, L Erhardt, C G Ericsson, et al.
American Heart Journal|May 1, 1986
Repeated exercise and redistribution thallium-201 scintigrams in patients with myocardial infarction treated with timolol or placeboC G Ericsson, A Hamsten, A Granath, et al.
Journal of Internal Medicine|April 25, 2006
Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarctionA Samnegård, A Silveira, P Tornvall, et al.
European Heart Journal|December 1, 1996
Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)U de Faire, C G Ericsson, L Grip, et al.
Lancet (London, England)|March 30, 1996
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patientsC G Ericsson, A Hamsten, J Nilsson, et al.
Pageof 3